Drug Profile

Research programme: Epidermal growth factor receptor targeted therapeutics - SpringWorks Therapeutics

Latest Information Update: 04 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Dana-Farber Cancer Institute; Stanford University School of Medicine
Developer Dana-Farber Cancer Institute; SpringWorks Therapeutics; Stanford University School of Medicine
Class Antineoplastics; Small molecules
Mechanism of Action Epidermal growth factor receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

01 Jul 2025 SpringWorks Therapeutics has been acquired by Merck KGaA
07 Nov 2022 Preclinical trials in Lung cancer (Combination therapy) in USA (unspecified route) (SpringWorks Therapeutics pipeline, November 2022)
07 Nov 2022 Preclinical trials in Lung cancer (Monotherapy) in USA (unspecified route) (SpringWorks Therapeutics pipeline, November 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com